Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies. Latest U.S.

I’ll admit to being surprised initially by the mid-month announcement that Regeneron Pharmaceuticals planned to buy out of bankruptcy most of the assets of 23andMe.

Regeneron Pharmaceuticals, which garnered attention in 2020 when President Donald Trump touted the company's experimental COVID-19 vaccine as a "cure," said Monday, May 19, that it will buy ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.

Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as expected in the third quarter of this year.